An antiandrogenic agent flutamide was used in the treatment of one male and 14 female postmenopausal breast cancer patients. Only a mild and transient response was seen in 2 female patients. Therefore, flutamide cannot be used solely in the treatment of female postmenopausal breast cancer.
Get full access to this article
View all access options for this article.
References
1.
BryanR.M., MercerR.J., BennettR.C., RennieG.C., LieT.H., MorganF.J.: Androgen receptors in breast cancer.Cancer, 54: 2436–2440, 1984.
2.
LippmanM., BolanG., HuffK.: The effects of androgens and antiandrogens on hormone responsive human breast cancer in long-term tissue culture.Cancer Res., 36: 4610–4618, 1976.
3.
PerelE., BlacksteinM.E., KillingerD.W.: Aromatase in human breast carcinoma.Cancer Res., (suppl.), 42: 3369s–3372s, 1982.
4.
SecretoG., RecchioneC., CavalieriA., MiragliaM., DatiV.: Circulating levels of testosterone, 17β-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients.Br. J. Cancer, 47: 269–275, 1983.
5.
SecretoG., TonioloP., BerrinoF., RecchioneC., Di PietroS., FariselliG., DecarliA.: Increased androgenic activity and breast cancer risk in premenopausal women.Cancer Res., 44: 5902–5905, 1984.
6.
SoganiP.C., VagaiwalaM.R., WhitmoreW.F.: Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy.Cancer, 54: 744–750, 1984.
